The use of ARBs as a potential breast cancer therapy would be predicted to have maximal success in patients with tumors expressing AT1R. As the AGTR1 gene is amplified in ER+ve/HER2−ve Grade II and III breast tumors [13], we assessed AT1R expression in human breast carcinoma samples. This evidence concerns the gene AGTR1 and breast carcinoma.